

| <b>Injectables/Injection (US FDA; EU GMP; WHO)</b> |                                    |                          |  |
|--|------------------------------------|--------------------------|--|
| <b>No.</b>   | <b>Product Name</b>                | <b>Strength</b>          | <b>Status</b>  |
| 1  | Ganciclovir Sodium for Injection   | 500mg                    | Marketed in DE, NL, FR, UK;<br>To be approved in US;   |
| 2  | Azithromycin for Injection         | 500mg                    | Tentative Approval in US;<br>To be approved in DE, NL, AT                                      |
| 3  | Levetiracetam Injection            | 500mg/5ml                | Approved in US, DE, NL   |
| 4  | Pantoprazole Sodium for Injection  | 40mg                     | Approved in DE, NL, AT;<br>To be approved in US  |
| 5  | Eptifibatide Injection             | 20mg/10ml,<br>75mg/100ml | Approved in NL;<br>To be approved in US  |
| 6  | Voriconazole for Injection         | 200mg                    | Q1, 2018 Submitted in US, EU   |
| 7  | Vancomycin for Injection           | 500mg, 1g<br>5g, 10g     | Q1, 2018 Submitted in US<br>Q2, 2019 Dossier ready for EU<br>Q2, 2019 Dossier ready for US, EU |
| 8  | Bivalirudin for Injection          | 250mg                    | Q3, 2018 Dossier ready for US, EU  |
| 9  | Terlipressin Injection             | 1mg/8.3ml                | Q1, 2019 Dossier ready for EU  |
| 10   | Sodium Nitroprusside for Injection | 25mg/ml                  | Q1, 2019 Dossier ready for US  |
| 11   | Daptomycin for Injection           | 350mg, 500mg             | Q2, 2019 Dossier ready for US, EU  |

|    |                                   |  |                                   |
|----|-----------------------------------|--|-----------------------------------|
| 12 | Tobramycin Sulfate for Injection  | 1.2g/vial                              | Q2, 2019 Dossier ready for US, EU |
| 13 | Esomeprazole Sodium for Injection | 20mg,40mg                              | Q2, 2019 Dossier ready for US, EU |
| 14 | Doxycycline for Injection         | 100mg,200mg                            | Q2, 2019 Dossier ready for US, EU |
| 15 | Amiodarone Injection              | 150mg:3ml,<br>450mg:9ml,<br>900mg:18ml | Q2, 2019 Dossier ready for US, EU |
| 16 | Dobutamine HCl Injection          | 250mg/20ml,<br>500mg/40ml              | Q2, 2019 Dossier ready for US, EU |
| 17 | Cyclophosphamide for Injection    | 500mg, 1g, 2g                          | Q2, 2019 Dossier ready for US, EU |
| 18 | Decitabine for Injection          | 50mg                                   | Q2, 2019 Dossier ready for US,EU  |
| 19 | Iohexol Injection                 | 30.2%,38.8%,5<br>1.8%,<br>64.7%,75.5%  | Q3, 2019 Dossier ready for US, EU |
| 20 | Tigecycline for Injection         | 50mg                                   | Q3, 2019 Dossier ready for US,EU  |
| 21 | Enoxaparin Injection              | 300mg/3ml                              | Q3, 2019 Dossier ready for US,EU  |
| 22 | Lincomycin Injection              | 300mg/ml                               | Q4, 2019 Dossier ready for US, EU |
| 23 | Sugammadex Sodium Injection       | 200mg/2ml,<br>500mg/5ml                | Q4, 2019 Dossier ready for US,EU  |
| 24 | Azacitidine for Injection         | 100mg                                  | Q4, 2019 Dossier ready for US,EU  |
| 25 | Carboplatin Injection             | 10mg/ml                                | Q4, 2019 Dossier ready for US,EU  |

|    |                                |                                    |                                  |
|----|--------------------------------|------------------------------------|----------------------------------|
| 26 | Calcium Leucovorin Injection   | 50, 100, 200, 350, 500mg Base/vial | Q4, 2019 Dossier ready for US,EU |
| 27 | Posaconazole Injection         | 300mg/16.7ml                       | Q1, 2020 Dossier ready for US,EU |
| 28 | Gadoteridol Injectable         | 279.3mg/ml                         | In pipeline                      |
| 29 | Iopamidol Injection            | 41%, 51%, 61%, 76%                 | In pipeline                      |
| 30 | Gadoterate Meglumine Injection | 376.9 mg/ml                        | In pipeline                      |
| 31 | Gadobutrol Injection           | 604.72 mg/ml                       | In pipeline                      |

<http://english.hnpoly.com/>

### Oral Solid Dosage (Chinese GMP)

| No. | Product Name                                     | Strength                             | Status   |
|-----|--|--------------------------------------|--|
| 1   | Desloratadine Tablets                            | 5mg                                  | Q4,2018 Dossier ready for EU                                   |
| 2   | Azithromycin for oral suspension                 | EQ 100mg base/5ml, EQ 200mg base/5ml | Q1, 2019 Dossier ready for EU<br>Q3, 2019 Dossier ready for US |
| 3   | Metformin hydrochloride Extended-release Tablets | 500mg                                | Q1,2019 Dossier ready for EU                                   |
| 4   | Levofloxacin Tablets                             | 250mg,500mg                          | Q1,2019 Dossier ready for EU, US                               |
| 5   | Trimebutine maleate Tablets                      | 0.1g,0.2g                            | Q1,2019 Dossier ready for EU                                   |
| 6   | Clarithromycin Extended Release Tablets          | 500mg                                | Q1,2019 Dossier ready for EU                                   |
| 7   | Azithromycin Tablets                             | 250mg                                | Q2,2019 Dossier ready for EU                                   |
| 8   | Desloratadine for Oral Suspension                | 2.5mg, 5mg                           | Q2,2019 Dossier ready for EU                                   |

|    |   |                        |   |
|----|---|------------------------|---|
| 9  | Diclofenac Sodium<br>Extended Release<br>Capsules   | 0.1g                   | Q2,2019 Dossier ready<br>for EU                                     |
| 10 | Oxcarbazepine Tablets                               | 150mg, 300mg,<br>600mg | Q2,2019 Dossier ready<br>for EU, US                                 |
| 11 | Desloratadine Dispersible<br>Tablets                | 5mg                    | Q3,2019 Dossier ready for<br>US, EU                                 |
| 12 | Omeprazole Enteric-<br>coated Capsules              | 10mg                   | Q4,2019 dossier ready for<br>EU<br>Q2, 2020 dossier ready<br>for US |
| 13 | Itraconazole Capsules                               | 100mg                  | Q1,2020 dossier ready for<br>EU<br>Q2, 2020 dossier ready<br>for US |
| 14 | Oxcarbazepine Oral<br>Suspension                    | 300mg/5ml              | Q2, 2020 dossier ready<br>for EU                                    |
| 15 | Dextromethorphan<br>Sustained Release<br>Suspension | 30mg/5ml               | Q2, 2020 dossier ready<br>for EU                                    |
| 16 | Topiramate Sustained<br>Release Capsule             | 25, 50,100,<br>200mg   | Q2, 2020 dossier ready<br>for EU, US                                |
| 17 | Fluconazole Oral<br>Suspension                      | 50mg/5ml,200<br>mg/5ml | Q2, 2020 dossier ready<br>for EU                                    |
| 18 | Loratadine Tablets                                  | 10mg                   | Q2, 2020 dossier ready<br>for EU, US                                |
| 19 | Linezolid Oral<br>Suspension                        | 100mg/5ml              | Q2, 2020 dossier ready<br>for EU                                    |
| 20 | Voriconazole Oral<br>Suspension                     | 200mg/5ml              | Q2, 2020 dossier ready<br>for EU, US                                |
| 21 | Trimebutine for Oral<br>Suspension                  | 4g:0.1g                | Q2,2020 Dossier ready for<br>US, EU                                 |
| 22 | Posaconazole Oral<br>Suspension                     | 40mg/ml                | Q3 2020 dossier ready for<br>EU                                     |

|   |   |                         |                                   |
|---|---|-------------------------|-----------------------------------|
| 23  | Clarithromycin Oral Suspension                              | 125mg/5ml;<br>250mg/5ml | Q4, 2020 dossier ready for EU, US |
| 24  | Pantoprazole Sodium Enteric Release Oral Suspension         | 40mg                    | Q1, 2021 dossier ready for EU     |
| 25  | Esomeprazole Magnesium for Oral Suspension(Delayed Release) |                         | Q1, 2021 dossier ready for EU     |
| 26  | Tamsulosin Hydrochloride Capsule                            | 0.4mg                   | In pipeline                       |
| 27  | Letrozole Tablet  | 2.5mg                   | In pipeline                       |
| 28  | Aripiprazole Tablet   | 2mg, 5mg,<br>10mg       | In pipeline                       |
| <a href="http://english.hnpoly.com/">http://english.hnpoly.com/</a> |   |                         |                                   |

Hainan Poly Pharm is an excellent finished product manufacturer in China, the injection facility is approved by EU twice(last Mar.2016) , WHO twice(last Aug.2014), and US FDA twice(last Jan.2016).

Cooperation Models:

- Contract Manufacturing: Injection(include oncology), SR Tablet/Capsule and Oral Suspension
- License the Product to China Market
- External Seek Technical Cooperation:
  - 1) Long-acting Injection; 2) Liposome Injection; 3) CR/SR Formulation; 4) Eye Drops; 5) Complex Injectables.











